NASDAQ: TECH

Bio-Techne (TECH) Stock Analysis & Forecast

Nov 13 close

$72.80−0.04 (−0.1%)

Gekko Brief

AI summaryNov 9 close

Bio-Techne's week centered on quarterly results and a pending acquisition. The company's first-quarter fiscal 2027 net sales rose 5% to $299.71 million, though net earnings declined to $28.29 million from $38.19 million, with diluted EPS of $0.18. A separate earnings report showed EPS of $0.42 against an estimate of $0.45, with revenue of $292.7 million short of the $293.03 million consensus. The board declared a quarterly dividend of $0.08 per share, payable 23 November 2026, contingent on the pending transaction with Merck KGaA not closing by 13 November 2026. Commentary also noted the stock trading above estimated intrinsic value on a discounted cash flow basis.

Shares closed at $72.83, up 0.1%, sitting above both the 50-day average of $72.49 and the 200-day average of $63.25, with the 50-day above the 200-day. The GekkoIndex reads 51.7, placing it in the Neutral zone, down 2.7 over five sessions. Price stands 24% above Gekko Fair Value of $58.72.

The next earnings date falls on 2 February 2027, 84 days out, beyond a typical 20-trading-day hold. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows. One billionaire holder and one trailblazer holder are recorded. Seasonally, the next 20 trading days have averaged a 1.8% gain over 5 years, positive in 3 of them. Analyst coverage from 4 firms shows 0 buy, 3 hold, and 1 sell, with a consensus target of $70.50.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Bio-Techne price vs fair value

$72.80$59.01Nov ’25May ’26Nov ’26
Close $72.80200-day averageGekko Fair Value $59.01

Bio-Techne quick facts

Market cap
$11.44B
P/E ratio
66.8
Forward P/E
35.7
EPS, TTM
$1.09
Revenue, TTM
$1.23B
Profit margin
14%
Dividend yield
0.33%
Beta
1.27
Volume
2.27M avg 2.87M
1-year return
+18.6%
Typical daily move
±0.2%
Typical 20-day move
±6.6%
50-day average
$72.53
200-day average
$63.38
Next earnings
Feb 2 before open
Shares outstanding
157.1M
52-week range
$43.20$72.88

Bio-Techne swing-trade checklist

Bio-Techne scores 3 supportive, 1 mixed and 1 headwind across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

3 supportive1 mixed1 headwind

  • Trendsupportive

    Above 50 and 200-day

    Close $72.80 is above the 50-day ($72.53) and 200-day ($63.38) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    53.1, Neutral

    Reading 53.1 is in the Neutral zone.

    See the GekkoIndex
  • Fair valueheadwind

    23.4% above

    Price is 23.4% above Gekko Fair Value (more than 5% above).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 79 days

    Next report Feb 2, 2027, 79 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +3.1% on average

    From this point in the calendar, the next 20 trading days averaged +3.1% over 5 years, rising in 3 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Bio-Techne stock chart and price history

Bio-Techne closed at $72.80 on Nov 13, 2026, +18.6% over the past year, inside a 52-week range of $43.20 to $72.88.

Close50-day average200-day averageVolume
Bio-Techne share price, past year, with 50-day and 200-day moving averages and volume$50$60$70DecJan 2026FebMarAprMayJunJulAugSepOctNov72.80

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+0.4%
3 months
+0.6%
6 months
+68.1%
1 year
+18.6%
The full TECH chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open TECH in Gekko

Follow Bio-Techne through every session

Put TECH on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track TECH in GekkoFree for 7 days. No credit card required.

About Bio-Techne

Bio-Techne makes and sells reagents, instruments, and services used across life science research, diagnostics, and bioprocessing work. It is recognized for its biological reagents such as cytokines, growth factors, antibodies, and cell selection tools, along with proteomic instruments built for automated western blot and multiplexed ELISA testing.

The company is structured into two segments. Its Protein Sciences segment supplies reagents and analytical instruments applied to research, diagnostics, and cell and gene therapy work, including protein quantification tools for biological fluids. Its Diagnostics and Genomics segment produces diagnostic controls, calibrators, and assays for regulated diagnostic markets, along with exosome-based molecular diagnostics, spatial genomic and tissue biopsy assays, and products used in genetic carrier screening, oncology diagnostics, hematology, blood chemistry, gases, and coagulation testing.

Bio-Techne was formerly named Techne Corporation before taking its current name in November 2014, and it was incorporated in 1976. It is headquartered in Minneapolis, Minnesota, and its shares are listed on the NASDAQ under the ticker TECH.

Listed
NASDAQ
Sector
Health technology
Industry
Biotechnology
Website
bio-techne.com

Bio-Techne GekkoIndex: the smart money zone

Bio-Techne’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 53.1, in the Neutral zone, up 0.8 points over five sessions.

010053.1Neutral

Up 0.8 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying38+0.9%+2.2%+3.3%−8.5%
Accumulation245+1.1%+1.6%+3.2%+4.3%
Neutral (current zone)376−0.4%−0.5%−0.8%+1.0%
Distribution37−0.2%−1.4%−3.6%−5.3%
Selling6Too few readings yet

Average TECH share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the TECH price, zone by zone.Track TECH in Gekko

Is Bio-Techne stock overvalued? Gekko Fair Value

Bio-Techne trades 23.4% above Gekko Fair Value of $59.01, so the shares are overvalued on Gekko’s estimate.

Gekko’s own estimate of what Bio-Techne shares are worth, recalculated every trading day.

$59.01

Gekko Fair Value, Nov 14, 2026

23.4% Overvalued

At the end of Aug 2026 the price was 39.3% above the estimate.

Gekko Fair ValueShare price, month end
$59$73Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open TECH in Gekko

Bio-Techne insider and Congress trading

No open-market insider purchases were filed for Bio-Techne, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for TECH in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every TECH insider filing, plotted on the chart in Gekko.Open TECH in Gekko

Congress trades last 90 days

No trades in TECH were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for TECH, plotted on the chart in Gekko.Open TECH in Gekko

Buybacks

Bio-Techne has been buying back its own shares.

Bought back, quarter ended Jun 30, 2026
$41.65M
As a share of market cap
0.36%

From company filings.

Hedge funds and billionaires quarter ended Jun 30

2of the funds Gekko tracks hold TECH.

0added1opened1trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko

Bio-Techne earnings: next date and track record

Bio-Techne reports on Feb 2, 2027, before the open (79 days away), and beat the EPS estimate in 6 of its last 8 reports.

6 of 8reports beat the EPS estimate
±4.6%average move across the report
4 of 8reports followed by a gain

Share-price move across each report

+4.3%Oct ’24+3.4%Feb ’25+4.3%May ’25−8.2%Aug ’25−4.8%Nov ’25+1.9%Feb ’26−10.2%May ’260.0%Aug ’26
ReportedEPSSurpriseRevenueSurpriseMove
Aug 12, 2026$0.52
est $0.52
+0.2%$321.2M
est $314.6M
+2.1%0.0%
May 6, 2026$0.00
est $0.54
−100.0%$311.4M
est $316.1M
−1.5%−10.2%
Feb 4, 2026$0.46
est $0.43
+7.0%$295.9M
est $290.5M
+1.9%+1.9%
Nov 5, 2025$0.42
est $0.42
−0.3%$286.6M
est $291.3M
−1.6%−4.8%
Aug 6, 2025$0.53
est $0.50
+6.1%$317.0M
est $294.6M
+7.6%−8.2%
May 7, 2025$0.56
est $0.51
+10.2%$316.2M
est $325.5M
−2.8%+4.3%
Feb 5, 2025$0.42
est $0.39
+7.7%$297.0M
est $317.5M
−6.5%+3.4%
Oct 30, 2024$0.42
est $0.38
+10.5%$289.5M
est $280.3M
+3.3%+4.3%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Bio-Techne stock forecast and analyst price targets

Analysts’ average 12-month price target for Bio-Techne is $70.50, −3.2% from the last close, from 3 firms rating the stock in the last 90 days.

$70.50consensus 12-month target, −3.2% from the last close
Buy0
Hold2
Sell1

Each firm’s latest rating in the last 90 days: 3 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 10Evercore ISIHold, maintained$73+0.3%
Nov 9RBC CapitalHold, maintained$73+0.3%
Oct 26Argus ResearchSell, downgraded——
−0.8%average 20-day move after past Neutral readings
+3.1%average move over the next 20 trading days in the last 5 years
±0.2%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Bio-Techne seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Bio-Techne averaged +3.1% across the last 5 years, rising in 3 of them.

Next 20 trading days, by year

−7.7%2021+0.8%2022+22.6%2023+4.3%2024−1.2%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−1.4%2 of 5
Next 10 trading days0.0%2 of 5
Next 15 trading days−0.8%2 of 5
Next 20 trading days+3.1%3 of 5
Next 30 trading days+3.8%2 of 5

For scale, TECH’s typical 20-trading-day move in either direction is about 6.6%.

Bio-Techne market cap and key statistics

Bio-Techne’s market cap is $11.44B, with a P/E ratio of 66.8 and revenue of $1.23B over the last twelve months.

Valuation

Market cap
$11.44B
P/E ratio
66.8
Forward P/E
35.7
EPS, TTM
$1.09
Gekko Fair Value
$59.01

Trading

Volume
2.27M
Avg volume, 20 days
2.87M
52-week high
$72.88
52-week low
$43.20
Shares outstanding
157.1M

Financials

Revenue, TTM
$1.23B
Profit margin
14%
Return on equity
8.3%
Quarterly earnings growth, YoY
−25.0%

Risk and income

Beta
1.27
Typical daily move
±0.2%
Typical 20-day move
±6.6%
Dividend yield
0.33%

Bio-Techne stock news this week

Coverage of Bio-Techne this week reads neutral: 1 positive, 4 neutral and 1 negative headlines.

News sentiment neutral

Bio-Techne peers

Bio-Techne’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
AMGNAmgen−0.4%Neutral19.9% below
GILDGilead Sciences−0.3%Neutral11.7% above
MRNAModerna−0.7%Neutral21.1% above
NTRANatera−1.8%Accumulation18.6% below
IQVIQVIA−2.4%Accumulation5.0% above
UTHRUnited Therapeutics−0.4%Neutral11.2% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Biotechnology

Bio-Techne stock FAQ

What is Bio-Techne’s market cap?

Bio-Techne’s market cap is $11.44B at the Nov 13, 2026 close of $72.80, with 157.1M shares outstanding. The shares trade on a P/E ratio of 66.8.

What is the Bio-Techne stock forecast?

The consensus analyst 12-month price target for Bio-Techne is $70.50, −3.2% from the last close. Of the 3 firms that rated the stock in the last 90 days, 0 rate it a buy, 2 a hold and 1 a sell. Gekko doesn’t publish price predictions of its own.

Is Bio-Techne stock overvalued or undervalued?

On Gekko’s estimate Bio-Techne is overvalued: the Nov 13, 2026 close of $72.80 is 23.4% above Gekko Fair Value of $59.01. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Bio-Techne report earnings next?

Bio-Techne is expected to report on Feb 2, 2027, before the market opens (79 days away). Analysts expect earnings of $0.47 per share on revenue of $308.7M. Bio-Techne beat the earnings estimate in 6 of its last 8 reports, moving 4.6% on average across the report.

What is Bio-Techne’s 52-week high and low?

Bio-Techne’s 52-week high is $72.88 and its 52-week low is $43.20; it closed at $72.80 on Nov 13, 2026, +18.6% over the past year. Over the last five years the shares peaked at $130.74 on Dec 31, 2021.

Is Bio-Techne stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, earnings risk and seasonality), 1 as mixed (gekkoindex) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Bio-Techne the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.